checkAd

     144  0 Kommentare SANUWAVE Health to Participate in Multiple U.S. Wound Care Medical Meetings in October - Seite 3

    About the dermaPACE System

    The dermaPACE System is a novel medical system based on shockwave technology, which has been used for nearly 30 years in lithotripsy procedures (destruction of kidney stones) and later in orthopedic treatments.  These early lithotripsy and orthopedic devices provided the earliest evidence that there was an effect on wound healing. Pulsed Acoustic Cellular Expression (PACE) Technology was developed based on this evidence, and the dermaPACE System is the first to utilize PACE-specific proprietary protocols for wound treatment.  The dermaPACE System treatment must be administered by a healthcare professional.  The dermaPACE System is FDA cleared for the treatment of diabetic foot ulcers (DFU) and it is the first and only system based on focused electrohydraulic shockwave principle cleared by the FDA for such indication.   For international markets, the dermaPACE System is CE Marked in Europe for advanced wound care indications and in Canada carries a Health Canada Medical Device class II License. The dermaPACE System is currently licensed or approved for advanced wound care indications in dozens of countries and regions around the world. 

    About SANUWAVE Health, Inc.

    SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.  Through its recent acquisition of Celularity’s UltraMIST assets, SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market. 

    SANUWAVE’s portfolio of regenerative medicine products and product candidates activate tissue regeneration biological signaling and angiogenic responses, producing new vascularization and microcirculatory improvement combined with tissue growth which helps restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac/endovascular conditions.

    Seite 3 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    SANUWAVE Health to Participate in Multiple U.S. Wound Care Medical Meetings in October - Seite 3 Highlighting the clinical advantages of the Company’s ‘Energy First’ approach to healing chronic wounds with dermaPACE and UltraMIST Systems SUWANEE, GA, Sept. 30, 2020 (GLOBE NEWSWIRE) - via NewMediaWire - SANUWAVE Health, Inc. (OTCQB: …